Richard van Zyl-Smit (University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa) kindly took the time to speak with us about maximising the benefit of inhaler therapy and recent development being made in this field.
- What are the major unmet needs in the use of inhaled therapies for the control of asthma? (0:15)
- How can we help patients optimise their inhaler technique? (0:55)
- How can we maximise the benefits of inhaler therapy over 24 hours? (1:46)
- Which asthma patients are most likely to benefit from once daily single inhaler triple therapy? (2:39)
- What have been the most exciting recent developments in inhaler therapy? (3:49)
Speaker disclosure: Richard van Zyl-Smith has conducted clinical research trials for Novartis, AstraZeneca, Takeda, Merck, Almirall, Boehringer Ingelheim, Sanofi, Teva, Perl, Pfizer, Roche, GSK and Genetech. He has also received honoraria for academic talks from, Aspen, Pfizer, AstraZeneca, Novartis, Cipla, MSD, Roche, Jannsen, Boehringer Ingelheim and participated in advisory boards for GSK, Pfizer, AstraZeneca, Novartis, MSD and Roche.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020
Share this Video
Related Videos In Asthma
Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma
It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma. Questions How can we further personalise treatment for people with severe asthma? (0:11) What are the hot topics and latest research you are looking […]
Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction. The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at […]
Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma. ‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!